Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts

Medicine and Dentistry

• Ras 100%
• Cells 60%
• Neoplasm 60%
• Cyclophosphamide 60%
• Antiangiogenic Therapy 60%
• Combination Therapy 40%
• Cancer Cell 40%
• Therapeutic Procedure 40%
• Ischemia 40%
• Tumor Progression 40%
• Mutagenesis 40%
• Low Drug Dose 40%
• DNA Mismatch Repair 40%
• Oncogene K Ras 40%
• In Vitro 20%
• Active Metabolite 20%
• Mutant 20%
• Colorectal Cancer 20%
• Oncogene 20%
• Colorectal Carcinoma 20%
• Hypoxia 20%
• Microvessel 20%
• Cancer Inhibition 20%
• Cancer Control 20%
• Alkylating Antineoplastic Agent 20%
• Xenograft 20%
• Antiangiogenic 20%
• Tumor Hypoxia 20%

Biochemistry, Genetics and Molecular Biology

• Mutation 80%
• Cyclophosphamide 60%
• Cancer Cell 40%
• Mutagenesis 40%
• Low Drug Dose 40%
• Tumor Progression 40%
• DNA Mismatch Repair 40%
• Oncogene K Ras 40%
• Electric Potential 20%
• Mouse 20%
• Mutant 20%
• Metabolite 20%
• Density 20%
• Oncogene 20%
• Growth Inhibition 20%
• Tumor Hypoxia 20%
• 4-Hydroxycyclophosphamide 20%